Dogwood Therapeutics is a clinical-stage biopharmaceutical company developing novel antiviral therapies for fibromyalgia and other diseases.
Dogwood Therapeutics has raised $12.5M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in January 2026.
Dogwood Therapeutics's investors include CK Life Sciences International, William Buchalter, Robert Buchalter.
Dogwood Therapeutics is headquartered in Alpharetta, United States.
Dogwood Therapeutics is a clinical-stage biopharmaceutical company developing novel antiviral therapies for fibromyalgia and other diseases.
Dogwood Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Dogwood Therapeutics — Funding & Investors." VCBacked, January 12, 2026, https://www.vcbacked.co/company/dogwood-therapeutics. Accessed October 1, 2026.
VCBacked. (2026). Dogwood Therapeutics — Funding & Investors. Retrieved October 1, 2026, from https://www.vcbacked.co/company/dogwood-therapeutics
{{cite web |title=Dogwood Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/dogwood-therapeutics |website=VCBacked |access-date=October 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated